Hormone therapy for menopausal symptoms: Tracking the translation of the Women's Health Initiative findings

Journal of Clinical Outcomes Management

Volumn 12, Issue 3, 2005, Pages 140-146

  Bastian, Lori A ^a   Breslau, Erica S ^b   Davis, William W ^b   Moser, Richard P ^b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEX HORMONE;

ACADEMIC ACHIEVEMENT; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH STATUS; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL ANALYSIS; TELEPHONE;

EID: 17644421798     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flashes: a systematic review. Climacteric 2001;4:58-74.
2. Voss S, Quail D, Dawson A, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. Euralox Investigators Group. BJOG 2002;109:874-85.
3. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-79.
4. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 2002;287:591-7.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002;288:321-33.
7. Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001;135:493-501.
8. Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer [published erratum appears in JAMA 2002;288:2544]. JAMA 2002;288:334-41.
9. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. Women's Health Initiative Investigators. JAMA 2003;290:1739-48.
10. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
11. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Women's Health Initiative Steering Committee. JAMA 2004;291:1701-12.
12. Grady D. Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003;348:1835-7.
13. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. U.S. Preventive Services Task Force. Ann Intern Med 2002;137:834-9.
14. Hulley SB, Grady D. The WHI estrogen-alone trial - do things look any better [editorial]? JAMA 2004;291:1769-71.
15. Ettinger B, Grady D, Tosteson AN, et al. Effect of the Women's Health Intitiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-32.
16. Grady D, Ettinger B, Tosteson AN, et al. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-9.
17. SUDAAN user's manual. Release 8.0. Research Triangle Park (NC): Research Triangle Institute; 2001.
18. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. Women's Health Initiative Investigators. N Engl J Med 2003;348:1839-54.
19. Breslau ES, Davis WW, Doner L, et al. The hormone therapy dilemma: women respond. J Am Med Womens Assoc 2003; 58:33-43.
20. Robinson TH, Patrick K, Eng TR, Gustafson D. An evidence-based approach to interactive health communication: a challenge to medicine in the information age. Science Panel on Interactive Communication and Health. JAMA 1998;280:1264-9.
21. Meissner HI, Rimer BK, Davis WW, et al. Another round in the mammography controversy. J Womens Health (Larchmt) 2003;12:261-76.
22. Keeter S, Miller C, Kohut A, et al. Consequences of reducing nonresponse in a national telephone survey. Public Opin Q 2000;64:125-48.
23. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15.
24. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. WHIMS Investigators. JAMA 2003;289:2663-72.
25. Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA 2003;289:895-902.
26. Gustafson D, Hawkins R, Boberg E, et al. Impact of a patient-centered computer-based health information/support system. Am J Prev Med 1999;16:1-9.
27. Walter LC, Davidowitz NP, Heineken PA, Covinsky KE. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure. JAMA 2004;291:2466-70.
28. Col NF, Weber G, Stiggelbout A, et al. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med 2004;164:1634-40.
29. Dobbins M, Ciliska D, Cockerill R, et al. A framework for the dissemination and utilization of research for health-care policy and practice. Online J Knowl Synth Nurs 2002;9:7.
30. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
31. Naylor CD. The complex world of prescribing behavior [editorial]. JAMA 2004;291:104-6.
32. Roter DL, Hall JA. Doctors talking with patients/patients talking with doctors: improving communication in medical visits. Westport (CT): Auburn House; 2002.
33. Haas JS, Kaplan CP, Gregorich SE, et al. Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk? J Gen Intern Med 2004;19:302-9.